title: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.
abstract: Cervical cancer (CC) is one of the most common malignancies in women. Paclitaxel is the front-line chemotherapeutic agent for treating CC. However, its therapeutic efficacy is limited because of chemoresistance, the mechanism of which remains poorly understood. Here, we used microRNA (miRNA) arrays to compare miRNA expression levels in the CC cell lines, HeLa and CaSki, with their paclitaxel resistance counterparts, HeLa/PR and CaSki/PR. We demonstrate that miR-125a was one of most significantly downregulated miRNAs in paclitaxel-resistant cells, which also acquired cisplatin resistance. And that the upregulation of miR-125a sensitized HeLa/PR and CaSki/PR cells to paclitaxel both in vitro and in vivo and to cisplatin in vitro. Moreover, we determined that miR-125a increased paclitaxel and cisplatin sensitivity by downregulating STAT3. MiR-125a enhanced paclitaxel and cisplatin sensitivity by promoting chemotherapy-induced apoptosis. Clinically, miR-125a expression was associated with an increased responsiveness to paclitaxel combined with cisplatin and a more favorable outcome. These data indicate that miR-125a may be a useful method to enable treatment of chemoresistant CC and may also provide a biomarker for predicting paclitaxel and cisplatin responsiveness in CC.
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Fan
authors.affiliation: Department of Oncology, 309th Hospital of PLA, Beijing, China.
authors.forename: H
authors.initials: H
authors.lastname: Cui
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.affiliation: Department of Orthopedics, PLA General Hospital, Beijing, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Ji
authors.affiliation: Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
authors.forename: L
authors.initials: L
authors.lastname: Kang
authors.affiliation: Department of Endocrinology and Metabolism, 264th Hospital of PLA, Shanxi, China.
authors.forename: B
authors.initials: B
authors.lastname: Han
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Dong
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Yan
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Yan
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Lin
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of Oncology, PLA General Hospital, Beijing, China.
authors.forename: S
authors.initials: S
authors.lastname: Jiao